Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $13,643 | 804 | 99.5% |
| Education | $56.01 | 4 | 0.4% |
| Consulting Fee | $12.55 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $3,271 | 193 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,975 | 151 | $0 (2024) |
| Gilead Sciences, Inc. | $1,291 | 60 | $0 (2024) |
| Janssen Biotech, Inc. | $868.90 | 55 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $810.06 | 43 | $0 (2024) |
| Merck Sharp & Dohme LLC | $647.61 | 38 | $0 (2024) |
| IRONWOOD PHARMACEUTICALS, INC | $628.01 | 38 | $0 (2024) |
| GENZYME CORPORATION | $429.12 | 14 | $0 (2024) |
| Synergy Pharmaceuticals Inc | $392.00 | 13 | $0 (2018) |
| PFIZER INC. | $388.93 | 25 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,984 | 151 | ABBVIE INC. ($408.64) |
| 2023 | $1,993 | 106 | AbbVie Inc. ($395.66) |
| 2022 | $2,045 | 117 | ABBVIE INC. ($545.84) |
| 2021 | $1,557 | 110 | AbbVie Inc. ($449.23) |
| 2020 | $1,064 | 79 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($369.09) |
| 2019 | $1,177 | 71 | AbbVie, Inc. ($363.79) |
| 2018 | $1,609 | 93 | AbbVie, Inc. ($441.61) |
| 2017 | $1,284 | 82 | AbbVie, Inc. ($362.97) |
All Payment Transactions
809 individual payment records from CMS Open Payments — Page 1 of 33
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), XIFAXAN | Food and Beverage | In-kind items and services | $23.43 | General |
| Category: Gastroenterology | ||||||
| 12/31/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), XIFAXAN | Food and Beverage | In-kind items and services | $14.12 | General |
| Category: Gastroenterology | ||||||
| 12/20/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $7.28 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/18/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $24.10 | General |
| Category: Rare Disease | ||||||
| 12/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $22.05 | General |
| Category: Immunology | ||||||
| 12/16/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $21.08 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/12/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $17.75 | General |
| Category: LIVER DISEASE | ||||||
| 12/11/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $9.34 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $22.02 | General |
| Category: Immunology | ||||||
| 12/09/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $21.57 | General |
| Category: Immunology | ||||||
| 12/04/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $28.12 | General |
| Category: THERAPY FOR CSID | ||||||
| 12/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), XIFAXAN | Food and Beverage | In-kind items and services | $11.93 | General |
| Category: Gastroenterology | ||||||
| 12/03/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $34.57 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/03/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $31.75 | General |
| Category: Immunology | ||||||
| 11/22/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.30 | General |
| 11/21/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/21/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $13.05 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $23.34 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $19.42 | General |
| Category: Rare Disease | ||||||
| 11/17/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $23.63 | General |
| Category: LIVER DISEASE | ||||||
| 11/15/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $9.57 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/14/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $26.90 | General |
| Category: HCV | ||||||
| 11/14/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.26 | General |
| 11/11/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $23.03 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $16.42 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 590 | 627 | $327,733 | $68,586 |
| 2022 | 15 | 695 | 762 | $384,997 | $82,867 |
| 2021 | 13 | 786 | 858 | $442,338 | $97,910 |
| 2020 | 16 | 733 | 951 | $357,843 | $80,042 |
All Medicare Procedures & Services
56 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 79 | 79 | $74,497 | $16,524 | 22.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 130 | 146 | $45,844 | $12,005 | 26.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 77 | 77 | $37,268 | $8,803 | 23.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 86 | 87 | $52,200 | $7,222 | 13.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 55 | 56 | $30,986 | $5,730 | 18.5% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 29 | 29 | $21,663 | $5,143 | 23.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 41 | 60 | $12,600 | $3,731 | 29.6% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 19 | 19 | $14,193 | $3,422 | 24.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 24 | 24 | $19,032 | $2,250 | 11.8% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 12 | 12 | $8,964 | $1,513 | 16.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 23 | 23 | $7,291 | $1,245 | 17.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 15 | 15 | $3,195 | $996.52 | 31.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 127 | 127 | $61,468 | $15,944 | 25.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 68 | 69 | $65,067 | $14,053 | 21.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 102 | 118 | $37,052 | $11,321 | 30.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 103 | 106 | $63,600 | $8,525 | 13.4% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 41 | 41 | $30,627 | $7,605 | 24.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 63 | 104 | $21,840 | $5,909 | 27.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 32 | 32 | $25,376 | $4,538 | 17.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 43 | 43 | $23,878 | $4,421 | 18.5% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 19 | 19 | $14,193 | $3,508 | 24.7% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 17 | 17 | $12,699 | $2,504 | 19.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 21 | 21 | $4,473 | $1,383 | 30.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 18 | 18 | $5,706 | $1,177 | 20.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 11 | 17 | $3,910 | $927.44 | 23.7% |
About Dr. Christopher Brown, MD
Dr. Christopher Brown, MD is a Gastroenterology healthcare provider based in Stockbridge, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2005. The National Provider Identifier (NPI) number assigned to this provider is 1194715813.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Brown, MD has received a total of $13,711 in payments from pharmaceutical and medical device companies, with $2,984 received in 2024. These payments were reported across 809 transactions from 40 companies. The most common payment nature is "Food and Beverage" ($13,643).
As a Medicare-enrolled provider, Brown has provided services to 2,804 Medicare beneficiaries, totaling 3,198 services with total Medicare billing of $329,404. Data is available for 4 years (2020–2023), covering 56 distinct procedure/service records.
Practice Information
- Specialty Gastroenterology
- Location Stockbridge, GA
- Active Since 10/25/2005
- Last Updated 09/05/2018
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1194715813
Products in Payments
- XIFAXAN (Drug) $1,640
- STELARA (Biological) $626.33
- Humira (Biological) $598.66
- DUPIXENT (Biological) $556.05
- Linzess (Drug) $535.94
- DIFICID (Drug) $516.10
- RINVOQ (Biological) $399.19
- Trulance (Drug) $392.00
- ENTYVIO (Biological) $389.89
- HUMIRA (Biological) $387.19
- XELJANZ (Drug) $343.08
- LINZESS (Drug) $340.35
- MAVYRET (Drug) $331.63
- Mavyret (Drug) $326.72
- OCALIVA (Drug) $317.25
- Entyvio (Biological) $315.70
- CREON (Drug) $283.74
- VIBERZI (Drug) $270.55
- INJECTAFER (Drug) $265.59
- ZENPEP (Drug) $245.93
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Stockbridge
Jai Eun Min, M.d, M.D
Gastroenterology — Payments: $15,418
Hitesh Chokshi, Md, MD
Gastroenterology — Payments: $13,010
Keval Patel, Md, MD
Gastroenterology — Payments: $12,342
Mark Edge, Md, MD
Gastroenterology — Payments: $10,720
Dr. Richard Mclean, M.d, M.D
Gastroenterology — Payments: $5,114
Dr. Timothy Gilrane, Md, MD
Gastroenterology — Payments: $66.81